Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Rhea-AI Summary

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the activation of Washington University School of Medicine in St. Louis as the first clinical site for the CLEER-001 Phase 2a clinical trial of HT-001. This trial targets rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy, which is significant for cancer patients undergoing treatment for various cancers, including non-small cell lung cancer and breast cancer. CEO Robb Knie emphasized the importance of this milestone in improving patient quality of life.

Positive

• Activation of Washington University as first clinical site for CLEER-001 trial.
• Phase 2a trial focuses on addressing skin disorders in cancer patients undergoing EGFR inhibitor therapy.

Negative

• None.

NEW YORK, March 8, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the activation of Washington University School of Medicine in St. Louis as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001 for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.

"Today's announcement is an important milestone as the Washington University School of Medicine in St. Louis becomes our first active site for this important clinical trial. The CLEER-001 clinical trial brings us one step closer to potentially improve the quality of life for cancer patients who need this novel therapeutic." said Robb Knie, CEO of Hoth Therapeutics, Inc.

Hoth is conducting the CLEER-001 clinical trial in the United States. Additional information and updates on the trial can be found by visiting Hoth's website and ClinicalTrials.Gov.

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options.  To learn more, please visit https://ir.hoththerapeutics.com/ .

Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates Hoth may develop, and the labeling under any approval Hoth may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of Hoth's products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on Hoth's business, its clinical trials, its research programs, healthcare systems or the global economy as a whole; Hoth's intellectual property; Hoth's reliance on third party organizations; Hoth's competitive position; Hoth's industry environment; Hoth's anticipated financial and operating results, including anticipated sources of revenues; Hoth's assumptions regarding the size of the available market, benefits of Hoth's products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding Hoth's goals, intentions, plans and expectations, including the introduction of new products and markets; and Hoth's cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place undue reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although Hoth believes that the expectations reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U.S. Securities and Exchange Commission. All such statements speak only as of the date of this press release. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:  LR Advisors LLC 
Email: investorrelations@hoththerapeutics.com 
www.hoththerapeutics.com 
Phone: (678) 570-6791

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-collaboration-with-first-active-clinical-site-for-its-phase-2-trial-to-treat-cancer-disorders-associated-with-epidermal-growth-factor-receptor-egfr-inhibitor-therapy-301765312.html

SOURCE Hoth Therapeutics, Inc.

FAQ

What is the purpose of Hoth Therapeutics' CLEER-001 clinical trial?

The CLEER-001 clinical trial aims to evaluate HT-001 for treating rash and skin disorders caused by EGFR inhibitor therapy in cancer patients.

Where is the CLEER-001 trial being conducted?

The CLEER-001 trial is being conducted in the United States, starting with Washington University School of Medicine in St. Louis.

What types of cancer are associated with EGFR inhibitors in this trial?

The trial is relevant for patients with non-small cell lung cancer, pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.

When was the CLEER-001 trial announced?

The CLEER-001 clinical trial was announced on March 8, 2023.

What are the next steps for Hoth Therapeutics following this announcement?

Hoth Therapeutics will proceed with the clinical trial and provide updates as the trial progresses.